Discovery of 5‑Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P‑Glycoprotein-Mediated Mutidrug Resistance
journal contributionposted on 2018-07-05, 00:00 authored by Bo Wang, Li-Ying Ma, Jing-Quan Wang, Zi-Ning Lei, Pranav Gupta, Yuan-Di Zhao, Zhong-Hua Li, Ying Liu, Xin-Hui Zhang, Ya-Nan Li, Bing Zhao, Zhe-Sheng Chen, Hong-Min Liu
P-glycoprotein (ABCB1)-mediated multidrug resistance (MDR) has become a major obstacle in successful cancer chemotherapy, which attracted much effort to develop clinically useful compounds to reverse MDR. Here, we designed and synthesized a novel series of derivatives with a 5-cyano-6-phenylpyrimidine scaffold and evaluated their potential reversal activities against MDR. Among these compounds, 55, containing an acylurea appendage, showed the most potent activity in reversing paclitaxel resistance in SW620/AD300 cells. Further studies demonstrated 55 could increase accumulation of PTX, interrupt ABCB1-mediated Rh123 accumulation and efflux, stimulate ABCB1 ATPase activity, and especially have no effect on CYP3A4 activity, which avoid drug interaction caused toxicity. More importantly, 55 significantly enhanced the efficacy of PTX against the SW620/AD300 cell xenograft without obvious side effects for orally intake. Given all that, the pyrimidine-acylurea based ABCB1 inhibitor may be a promising lead in developing new efficacious ABCB1-dependent MDR modulator.
Read the peer-reviewed publication
Acylurea Moietycompoundside effectsPTXcancer chemotherapyOrally Bioavailable Reversal Agentspaclitaxel resistancenovel seriesABCB 1 ATPase activityABCB 1 inhibitor5- cyano -6-phenylpyrimidine scaffolddrug interactionreversal activitiesABCB 1-dependent MDR modulatorSWacylurea appendageCYP 3A activityABCB 1-mediated Rh 123 accumulation